COPD exacerbationMANAGEMENT

RESPIRATORY PRESENTATIONS · 12 SECTIONS

⚲

520 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Acute bronchitis Acute Respiratory Distress Syndrome (ARDS)Acute respiratory failure Apparent Life-Threatening Event (ALTE-BRUE)Aspiration pneumonia Asthma exacerbation Bacterial Tracheitis Bronchiolitis Bronchiolitis (RSV)Chylothorax Community-acquired pneumonia COPD exacerbation COVID-19 pneumonia Croup Croup (laryngotracheobronchitis)Cystic Fibrosis Exacerbation Empyema Epiglottitis Epiglottitis (Pediatric)Fat Embolism Syndrome Foreign Body Aspiration Foreign Body Aspiration (Pediatric)Healthcare-Associated Pneumonia Hemothorax Hospital-acquired pneumonia Legionnaires' Disease Lung Abscess Pertussis Pleural effusion Pleurisy Pneumocystis jirovecii Pneumonia Pneumocystis Pneumonia Pneumomediastinum Pneumothorax (Simple)Pneumothorax (traumatic)Psittacosis Pulmonary Alveolar Proteinosis Pulmonary contusion Pulmonary Edema (Non-cardiogenic)Sarcoidosis Exacerbation Smoke Inhalation Injury Spontaneous pneumothorax Status Asthmaticus Sudden Infant Death Syndrome (SIDS)Tension Pneumothorax Tracheal Stenosis Viral Pneumonia

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Pediatric-Specific Presentations13▾

Endocrine and Metabolic Presentations42▾

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp52

Triage and immediate risks

›Immediate stabilization priorities

›Airway protection concerns

›Inability to speak full sentences

›Copious secretions with poor clearance

›Breathing failure concerns

›SpO2 persistently < 88% despite oxygen

›Rising PaCO2 with pH < 7.35

›Circulatory failure concerns

›Hypotension or shock physiology

›New malignant arrhythmia

›High risk phenotypes

›Altered mental status or somnolence

›Silent chest with minimal air movement

›Severe accessory muscle use with fatigue

Initial monitoring and targets

›Monitoring and targets

›Continuous pulse oximetry

›SpO2 target 88% to 92%

›If chronic hypercapnia unknown, start 88% to 92% and reassess with blood gas

›Cardiac monitoring

›Bronchodilator associated tachyarrhythmia risk

›Concurrent ACS risk in COPD population

›Frequent respiratory reassessment

›Work of breathing trajectory

›Ability to speak and protect airway

›Blood pressure trend

›Dynamic hyperinflation related hypotension concern

Ventilatory support escalation

›Escalation framework

›Supplemental oxygen escalation

›Nasal cannula then Venturi mask for controlled FiO2

›Avoid high FiO2 without reassessment in CO2 retainers

›Noninvasive ventilation pathway

›If acute hypercapnic respiratory acidosis

›If severe dyspnea with respiratory muscle fatigue

›Intubation pathway

›If NIV contraindication or failure

›If inability to protect airway

›Immediate resuscitation bay triggers

›pH < 7.25 or rapidly worsening gas exchange

›Hemodynamic instability

›Rising PaCO2 with declining mental status

Key concepts

›Core physiologic problems

›Airflow limitation with expiratory flow collapse

›Air trapping and dynamic hyperinflation

›Increased work of breathing and fatigue

›Ventilation perfusion mismatch

›Hypoxemia common

›Hypercapnia common in advanced disease

›Common precipitants

›Viral respiratory infection

›Bacterial infection

›Environmental irritants

›Medication nonadherence or poor inhaler technique

02History/hx73

Presenting features and triggers

›Symptom pattern

›Dyspnea worse than baseline

›Onset timeline hours to days

›Functional decline compared with usual

›Sputum change

›Increased volume

›Increased purulence

›Cough change

›Increased frequency

›New nocturnal cough

›Wheeze or chest tightness

›Poor relief with home bronchodilator

›Increased rescue inhaler use

›Exacerbation triggers

›Recent viral syndrome

›Sick contacts

›Fever history

›Environmental exposure

›Smoke or wildfire exposure

›Cold air or pollution

›Medication factors

›Running out of inhalers

›Recent sedative or opioid use

›Cardiopulmonary alternate triggers

›Chest pain suggestive of ACS

›Unilateral leg swelling or pleuritic pain suggesting PE

Baseline severity and risk stratification

›Baseline COPD severity

›Home oxygen use

›Baseline flow rate

›Baseline target saturation plan

›Prior ICU or intubation for COPD

›Prior NIV success or failure

›Prior difficult airway history

›Exacerbation history

›Number in last 12 months

›Recent antibiotics or steroids exposure

›Baseline exercise tolerance

›Baseline dyspnea grade

›Ability to perform ADLs

›Infection and resistance risks

›Recent hospitalization or antibiotics within 90 days

›Risk for resistant organisms

›Risk for C difficile with repeated antibiotics

›Bronchiectasis history

›Pseudomonas risk

›Frequent purulent sputum baseline

›Immunosuppression

›Chronic systemic steroids

›Biologic or chemotherapy exposure

Comorbidities and medication review

›Comorbidities

›Heart failure history

›Orthopnea and edema baseline

›Recent weight gain

›Coronary disease

›Typical or atypical angina

›Recent exertional symptoms

›Sleep disordered breathing or obesity hypoventilation

›Baseline hypercapnia risk

›Home CPAP or BiPAP use

›Venous thromboembolism history

›Prior PE or DVT

›Anticoagulant use and adherence

›Medication and device review

›Inhaled therapies

›LAMA use

›LABA use

›ICS use and pneumonia risk

›Exacerbation therapies already taken

›Steroid dose and timing

›Antibiotic name and timing

›Inhaler technique and adherence barriers

›Spacer availability

›Nebulizer access

03Physical Exam/exam44

Respiratory assessment

›Work of breathing

›Accessory muscle use

›Intercostal retractions

›Abdominal paradox

›Speech and fatigue

›One word responses

›Inability to lie flat

›Respiratory rate extremes

›Marked tachypnea

›Bradypnea suggesting fatigue

›Auscultation and airflow

›Diffuse wheeze

›Bronchospasm phenotype

›Response to bronchodilator over time

›Reduced breath sounds

›Severe obstruction or fatigue

›Pneumothorax consideration if asymmetric

›Focal crackles or bronchial sounds

›Pneumonia consideration

›Heart failure overlap consideration

Hemodynamics and systemic findings

›Vital signs pattern

›Fever

›Infectious trigger likelihood

›Alternate source consideration

›Tachycardia

›Hypoxemia or bronchodilator effect

›PE or sepsis consideration

›Hypotension

›Sepsis physiology

›Dynamic hyperinflation effect

›Mental status and perfusion

›Somnolence or confusion

›Hypercapnia concern

›Hypoxemia concern

›Diaphoresis and exhaustion

›Impending ventilatory failure

›Need for escalation of support

PITFALLS

›Common examination pitfalls

›Wheeze absence does not exclude severe obstruction

›Silent chest concern

›Fatigue and low airflow concern

›Peripheral edema can reflect cor pulmonale or heart failure overlap

›BNP and imaging correlation need

›Diuretic decision individualized

04Differential Diagnosis/ddx36

Life threatening and must not miss

›High risk alternatives

›Pneumonia

›ICD-10 J18.9

›Focal findings or infiltrate on imaging

›Pulmonary embolism

›ICD-10 I26.99

›Pleuritic pain or unexplained tachycardia

›Acute coronary syndrome

›ICD-10 I21.9

›Dyspnea as anginal equivalent

›Acute decompensated heart failure

›ICD-10 I50.9

›Orthopnea and pulmonary edema imaging

›Pneumothorax

›ICD-10 J93.9

›Unilateral decreased breath sounds and sudden deterioration

Mimics and overlapping syndromes

›Common mimics

›Asthma exacerbation

›ICD-10 J45.901

›Prior atopy or variable symptoms

›Upper airway obstruction

›Stridor phenotype

›Poor response to bronchodilator

›Medication related hypoventilation

›Opioid or sedative exposure

›Small pupils or low respiratory drive

›Metabolic acidosis driving tachypnea

›DKA or sepsis physiology

›Low HCO3 minus on chemistry

COPD specific complications

›COPD complications

›Hypercapnic encephalopathy

›Acute rise in PaCO2 with mental status change

›NIV response monitoring

›Cor pulmonale decompensation

›Peripheral edema and JVP elevation

›RV strain signs on ECG or ultrasound

05Laboratory Tests/lt34

Core labs and interpretation

›Core laboratory evaluation

›Blood gas selection

›VBG for pH and PaCO2 trend

›ABG if precise oxygenation or severe instability

›Electrolytes and renal function

›Potassium and magnesium for arrhythmia risk

›Creatinine for medication dosing and disposition

›Glucose

›Steroid induced hyperglycemia risk

›Infection stress hyperglycemia

›Infectious evaluation

›CBC

›Leukocytosis supportive but nonspecific

›Eosinophilia suggesting steroid responsive phenotype

›CRP or procalcitonin if used locally

›Antibiotic stewardship adjunct

›Not a sole rule out for bacterial infection

Cardiac and overlap evaluation

›Cardiac overlap labs

›Troponin if chest pain or high risk features

›Type 2 injury common in hypoxemia

›ACS evaluation pathway if rising pattern

›BNP or NT proBNP if heart failure overlap suspected

›Higher values support volume overload physiology

›Lower values reduce likelihood of heart failure

Microbiology and targeted testing

›Microbiology

›Sputum culture indications

›Frequent exacerbations with purulent sputum

›Suspected Pseudomonas or bronchiectasis

›Viral testing indications

›Influenza and SARS CoV 2 during circulation

›Infection control and targeted antivirals

›Lactate

›Sepsis concern with hypotension or fever

›Beta agonist related lactate elevation interpretation caution

06Diagnostic Tests/dt48

Scoring Systems

›Risk stratification tools

›DECAF score for hospitalized AECOPD prognosis

›Dyspnea grade

›Eosinopenia

›Consolidation on imaging

›Acidemia

›Atrial fibrillation

›BAP 65 score for severity assessment

›BUN elevation

›Altered mental status

›Pulse elevated

›Age 65 or older

›Use limitations

›Not a replacement for bedside trajectory assessment

›Limited utility for ED discharge decisions in isolation

MRI

›MRI role

›Not routine for AECOPD

›Limited availability and time sensitivity mismatch

›Motion artifact with tachypnea

›Alternative diagnosis scenarios

›Suspected spinal cord or CNS process driving hypoventilation

›Evaluation of mediastinal mass if CT contraindicated

›CT chest indications

›PE evaluation pathway

›CT pulmonary angiography when pretest probability warrants

›D dimer strategy in low risk patients per local protocol

›Complication evaluation

›Suspected pneumothorax not clear on x ray

›Severe hemoptysis evaluation

›Pneumonia complications

›Suspected abscess or empyema

›Persistent severe symptoms despite therapy

›CT considerations in COPD

›Contrast nephropathy risk assessment

›Hyperinflation and bullous disease recognition

Ultrasound (or US)

›Point of care ultrasound applications

›Lung ultrasound

›B lines supporting pulmonary edema

›Consolidation suggesting pneumonia

›Pleural evaluation

›Pleural effusion detection

›Pneumothorax signs

›Cardiac ultrasound

›LV function estimate for heart failure overlap

›RV strain signs for PE concern

›IVC assessment

›Volume status adjunct

›Interpret with clinical context and ventilation effects

07Disposition/dispo27

Level of care decisions

›Admission and higher level care criteria

›ICU or step down triggers

›NIV requirement

›pH < 7.30 or worsening hypercapnia

›Ward admission triggers

›Persistent hypoxemia needing oxygen above baseline

›Inadequate response to ED bronchodilators

›Transfer considerations

›Need for ICU without local capacity

›Anticipated difficult airway with limited resources

ED discharge criteria and follow up

›Discharge suitability

›Clinical stability after therapy

›Work of breathing near baseline

›SpO2 at target on baseline oxygen or room air

›Home supports adequate

›Ability to obtain medications and devices

›Caregiver support if frail

›No concerning alternate diagnosis

›No ischemic symptoms requiring workup

›No imaging or exam suggesting pneumonia requiring admission

›Follow up plan

›Primary care or respirology follow up

›Within 2 to 7 days if moderate exacerbation

›Earlier if frequent exacerbator phenotype

›Smoking cessation and vaccination update

›Influenza and pneumococcal status review

›Pulmonary rehabilitation referral when appropriate

08Treatment/t101

Oxygen and ventilatory support

›Respiratory support strategy

›Controlled oxygen

›SpO2 target 88% to 92%

›Venturi mask for precise FiO2 when needed

›Noninvasive ventilation

›Indications

›pH 7.25 to 7.35 with elevated PaCO2

›Severe dyspnea with accessory muscle use

›Initial settings example

›IPAP 10 to 15 cmH2O

›EPAP 4 to 6 cmH2O

›Titration targets

›Reduced work of breathing

›Improving pH and PaCO2 within 1 to 2 hours

›Contraindications

›Inability to protect airway

›Hemodynamic instability

›Intubation and invasive ventilation

›Indications

›NIV failure with worsening acidosis

›Refractory hypoxemia

›Ventilation principles

›Low respiratory rate with prolonged expiratory time

›Permissive hypercapnia with pH tolerance individualized

Bronchodilators

›Short acting bronchodilator regimen

›Salbutamol nebulized

›2.5 to 5 mg every 20 minutes for 3 doses

›Then every 1 to 4 hours as needed

›Ipratropium nebulized

›0.5 mg every 20 minutes for 3 doses

›Then every 4 to 6 hours

›Metered dose inhaler alternative

›Salbutamol 4 to 8 puffs via spacer

›Ipratropium 4 to 8 puffs via spacer

›Adverse effect monitoring

›Tachycardia and tremor

›Hypokalemia risk with high dose beta agonist

Systemic corticosteroids

›Steroid therapy

›Prednisone oral

›40 mg daily

›Typical duration 5 days

›Methylprednisolone IV alternative

›40 mg IV daily when unable to take oral

›Transition to oral when feasible

›Key effects

›Improved FEV1 and dyspnea

›Reduced treatment failure and relapse

›Safety considerations

›Hyperglycemia monitoring

›Delirium risk in older adults

Antibiotics

›Antibiotic decision framework

›Indications consistent with bacterial trigger

›Increased sputum purulence

›Increased sputum volume

›Increased dyspnea

›Ventilation related indication

›NIV requirement

›Intubation requirement

›Outpatient regimen examples

›Amoxicillin clavulanate

›875 mg orally twice daily

›Duration 5 to 7 days

›Doxycycline

›100 mg orally twice daily

›Duration 5 to 7 days

›Azithromycin

›500 mg orally once then 250 mg daily

›Duration 5 days

›Inpatient regimen considerations

›Ceftriaxone plus azithromycin if pneumonia overlap

›Antipseudomonal coverage if risk factors present

›Risk factors for Pseudomonas

›Bronchiectasis

›Prior Pseudomonas culture

›Recent broad spectrum antibiotics

Adjuncts and special therapies

›Additional therapies

›Magnesium sulfate IV

›Not routine for COPD

›Consider only if strong asthma overlap phenotype

›Mucolytics and airway clearance

›Hydration and expectoration support

›Physiotherapy if copious secretions

›Diuretics

›If clear heart failure overlap

›Avoid empiric diuresis without supportive findings

›Venous thromboembolism prophylaxis

›Pharmacologic prophylaxis for admitted patients unless contraindicated

›Mechanical prophylaxis if bleeding risk

Evidence levels and guideline alignment

›Guideline and evidence notes

›Systemic corticosteroids and short acting bronchodilators core therapy

›Class I recommendation in major COPD guidelines

›Reduced relapse and improved lung function

›Noninvasive ventilation for acute hypercapnic respiratory failure

›Class I recommendation in ATS ERS guidance

›Reduced need for intubation and mortality

›Antibiotics when increased sputum purulence plus other symptoms or ventilation required

›Guideline supported

›Benefit greatest in severe exacerbations

›ACEP evidence labeling usage note

›ED COPD specific ACEP Level A B C varies by topic

›Use local ED pathways for formal ACEP linkage when available

09Special Populations/sp30

Pregnancy

›Pregnancy considerations

›Maternal oxygenation priority

›SpO2 target at least 95% if fetal concerns

›Balance with hypercapnia risk using blood gas reassessment

›Medication safety

›Short acting bronchodilators acceptable

›Systemic steroids acceptable when needed

›Imaging and PE assessment

›VTE risk increased in pregnancy

›Radiation minimizing pathway per local protocol

Geriatric

›Older adult considerations

›Delirium risk

›Hypercapnia and hypoxemia contribution

›Steroid related agitation

›Comorbidity overlap

›Heart failure and pneumonia common

›Polypharmacy including sedatives

›Disposition threshold lower

›Frailty and poor reserve

›Need for close follow up and home supports

Pediatrics

›Pediatric considerations

›True COPD rare

›Alternate diagnosis more likely

›Asthma and bronchiolitis common

›If known early onset obstructive disease

›Cystic fibrosis bronchiectasis overlap

›Congenital airway disorders

›Weight based dosing requirement

›Nebulized bronchodilators by weight

›Early pediatric consultation

10Background/b33

Epidemiology

›Epidemiology highlights

›COPD definition

›Persistent airflow limitation with chronic respiratory symptoms

›SNOMED CT term chronic obstructive lung disease

›Exacerbation impact

›Accelerated lung function decline

›Increased mortality risk after severe exacerbation

›Common ICD-10 coding

›COPD with acute exacerbation ICD-10 J44.1

›Acute respiratory failure with hypercapnia ICD-10 J96.02

Pathophysiology

›Pathophysiologic mechanisms

›Bronchial inflammation and mucus

›Increased airway resistance

›Mucus plugging and atelectasis risk

›Emphysema and loss of elastic recoil

›Air trapping and hyperinflation

›Reduced inspiratory capacity

›Gas exchange abnormalities

›VQ mismatch driving hypoxemia

›Hypoventilation driving hypercapnia

Therapeutic Considerations

›Therapy rationale

›Short acting bronchodilators

›Bronchospasm reduction

›Improved expiratory flow and symptom relief

›Systemic steroids

›Reduced airway inflammation

›Shorter recovery and reduced relapse

›Antibiotics in selected patients

›Bacterial load reduction

›Prevent treatment failure in severe cases

›Noninvasive ventilation

›Reduced work of breathing

›Improved alveolar ventilation and pH

11Patient Discharge Instructions/pdi27

copy discharge instructions

›Discharge instructions for COPD flare

›Medication plan

›Rescue inhaler use as prescribed

›Steroid course completion if prescribed

›Antibiotic plan if prescribed

›Complete full course

›Diarrhea or rash prompt medical advice

›Oxygen guidance

›Use oxygen as prescribed

›Target saturation plan if provided

›Activity and recovery

›Gradual return to normal activity

›Hydration and airway clearance measures

›Follow up

›Primary care or respirology within 2 to 7 days

›Inhaler technique review at follow up

›Return to ED immediately if

›Severe shortness of breath at rest

›Blue lips or fingers

›Confusion or extreme sleepiness

›Chest pain or fainting

›SpO2 below target despite usual oxygen

›Unable to speak in full sentences

›Prevention

›Smoking cessation support

›Vaccination discussion at follow up

›Pulmonary rehabilitation discussion when stable

12References/r15

Clinical guidelines and evidence sources

›Global Initiative for Chronic Obstructive Lung Disease COPD report

›Exacerbation diagnosis and severity assessment guidance

›Pharmacologic and ventilatory management recommendations

›ATS ERS clinical practice guideline on noninvasive ventilation for acute respiratory failure

›NIV indications for COPD with hypercapnic acidosis

›NIV outcomes including reduced intubation and mortality

›NICE guideline on chronic obstructive pulmonary disease in over 16s

›Antibiotic selection guidance for exacerbations

›Discharge and follow up recommendations

›Cochrane systematic reviews on systemic corticosteroids in AECOPD

›Reduced treatment failure and relapse

›Adverse effects including hyperglycemia

›Cochrane systematic reviews on antibiotics for AECOPD

›Benefit in severe exacerbations and ventilated patients

›Stewardship considerations

Learn More: COPD exacerbation→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.